Trastuzumab-strf (Hercessi)
Reconstitution and dilutionFull monograph review pending
U.S. label preparation
Hercessi · Reconstitution and dilution
- Preparation
- 150 mg single-dose vial: add 7.4 mL sterile water for injection. 420 mg multidose vial: add 20 mL bacteriostatic water for injection. For benzyl alcohol hypersensitivity, the 420 mg vial may use 20 mL preservative-free sterile water for one-time use. Both produce 21 mg/mL.
- Administration and handling
- Add the prescribed reconstituted volume to a bag containing 250 mL of 0.9% sodium chloride. Avoid dextrose. Verify that the vial contains trastuzumab-strf.
Product and source details
Accord BioPharma Inc. · BLA761346
Product NDC: 69448-015, 69448-016
SPL effective 2026-10-02 | SPL version 6. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.